Source comparison
PT-141 Dosage Guide: Clinical Comparison Table
0.25 1.2–1.8 50–70 <5% +2 to +4 Initial titration, receptor sensitivity screening Minimal melanocortin activation. Useful for baseline measurement but sub-therapeutic for arousal outcomes 0.5 2.8–3.5 45–65 8–10% +3 to +6 Early titration, pediatric analogs (non
This comparison does not assign a generated winner or score.
- 0.25
- 1.2–1.8
- 50–70
- <5%
- +2 to +4
- Initial titration, receptor sensitivity screening
- Minimal melanocortin activation. Useful for baseline measurement but sub-therapeutic for arousal outcomes
- 0.5
- 2.8–3.5
- 45–65
- 8–10%
- +3 to +6
- Early titration, pediatric analogs (non-sexual research)
- Threshold for subjective effects in 15–20% of subjects. Not adequate for primary endpoint measurement
- 1.0
- 5.5–7.2
- 45–60
- 15–18%
- +5 to +9
- Intermediate titration, dose-response studies
- First dose with consistent MC4R activation. Viable maintenance dose for subjects intolerant of 1.75mg
- 1.75
- 10.8–13.4
- 26–30%
- +8 to +12
- FDA-approved therapeutic dose, standard for human sexual arousal research
- Optimal balance of efficacy and tolerability. Highest dose with favorable risk-benefit ratio
- 2.0
- 12.1–15.0
- 40–55
- 40–44%
- +10 to +15
- Rarely used. No additional efficacy vs 1.75mg
- Increases adverse events without improving outcomes. Not recommended outside of pharmacokinetic studies
- This table reflects pooled data from the RECONNECT Phase III trials (N=1,267 premenopausal women) and subsequent pharmacokinetic studies. The 1.75mg dose represents the point where additional melanocortin receptor activation no longer translates to measurable improvement in primary endpoints (satisfying sexual events, desire scores on the FSFI scale) but does increase the incidence of dose-limiting adverse events. For research protocols comparing PT-141 to placebo or other interventions, 1.75mg is the standard active comparator dose.